Sartorius Stedim Biotech (OTCMKTS:SDMHF) Trading Down 5% – Here’s What Happened

Sartorius Stedim Biotech S.A. (OTCMKTS:SDMHF)’s stock price fell 5% on Tuesday . The stock traded as low as $193.54 and last traded at $193.54. 50 shares changed hands during trading, a decline of 98% from the average session volume of 2,588 shares. The stock had previously closed at $203.75.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SDMHF. Barclays reiterated an “overweight” rating on shares of Sartorius Stedim Biotech in a report on Tuesday, January 6th. The Goldman Sachs Group cut Sartorius Stedim Biotech from a “buy” rating to a “neutral” rating in a research note on Monday, January 12th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold”.

Sartorius Stedim Biotech Stock Down 5.0%

The business has a 50 day moving average of $205.15 and a two-hundred day moving average of $224.53.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.